Company intelligence / Profile preview
AvenCell Therapeutics
Cambridge/WATERTOWN, Massachusetts, United Statesavencell.com ↗
- Ownership
- Private
- Employees
- ~200
- Development stage
- Phase 1
01
Overview
AvenCell has demonstrated controllability of its Universal CAR-T Cells with manageable toxicity in early clinical studies. Its lead program AVC‑101 targets CD123 for relapsed/refractory AML. The company’s allogeneic program AVC‑201 has received EMA approval for a clinical trial application. Early data show safety and efficacy signals for their universal CAR-T approach.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Universal switchable CAR-T cell therapies (autologous and allogeneic)adoptive T cell therapy
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
03
Partnerships
Blackstone Life Sciences (founder/investor)Cellex Cell ProfessionalsIntellia Therapeutics (CRISPR/Cas9 license)
Beyond the preview
Go deeper on AvenCell Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AvenCell Therapeutics.